Skip to content

Comparative bioavailability study of four different Curcumin formulations in 20 Healthy adult human male subjects under fasting conditions.

An open label, balanced, randomized, parallel, single dose, comparative bioavailability study of four different Curcumin formulations (containing Curcumin 600mg) of Sanat Products Ltd., India in 20 Healthy adult human male subjects under fasting conditions.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/07/005993
Enrollment
20
Registered
2015-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Turmix Capsule : 600mg / 2 cap of Sanat Products Ltd., India single dose, duration-one day Intervention2: Alzeimeromin Capsule : 600mg / 2 cap of Sanat Products Ltd., India sin

Sponsors

Sanat Products Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Subject who are able and ready to provide written informed consent. ii. Subjects must be healthy male human beings within 18-45 years of age (both inclusive). iii. Subjects should be having Body Mass Index (BMI) in the range 18.5-30 kg/m2, weighing at least 50 kg. iv. Subjects must be of normal health as determined by medical history, physical examination, ECG and laboratory tests performed within 21 days prior to the commencement of the study. v. Subjects whose screening laboratory values are within normal limits or considered by the physician / Principal Investigator to be of no clinical significance

Exclusion criteria

Exclusion criteria: i. Subjects incapable of understanding the informed consent process or not ready to sign informed consent. ii. Subjects with significant history of hypersensitivity to Curcumin or any ingredients of the formulation or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs. iii. Subject with of presence or history of significant gastrointestinal, liver or kidney disease, or any conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. iv. Subjects with active peptic ulceration or a history of peptic ulceration. v. Subject with resting hypotension (BP 139 /89). vi. Subject with Pulse rate 50/ min. and above 99/min. vii. Subjects with or prior history of clinically significant, Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease. viii. Subjects with a history of MI, Stroke, Peripheral Arterial Disease, GI Bleeding, Hepatic-Impairment, Renal Impairment, Epilepsy and Intracranial hemorrhage. ix. Subjects with a history of known food allergy. x. Subjects who have suffered any illness or who have been hospitalized within the last 4 weeks preceding the start of the study.

Design outcomes

Primary

MeasureTime frame
To assess the bioavailability of single oral formulation of four different Curcumin formulations (containing Curcumin 600mg) of Sanat Products Ltd., India in 20 Healthy adult human male subjects under fasting conditions.Timepoint: Pre dose (00.00 hour) sample will be collected within 02 hours prior to Investigational Product administration and the post dose samples will be collected at 00.25, 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.50, 03.00, 04.00, 06.00, 08.00 and 10.00 hours respectively.

Secondary

MeasureTime frame
To monitor adverse events and assess safety and tolerability of Curcumin under fasting condition.Timepoint: Vital signs - sitting blood pressure, radial pulse rate, oral temperature will be assessed at admission, prior to dosing (00.00 hrs) and at 02.00, 06.00 and 12.00 hours post-dose and at the time of checkout (24.00 hrs).

Countries

India

Contacts

Public ContactDr Manoj Karwa

Sanat Products Ltd.,

bdhasan@sanat.co.in05735-222415

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026